Form 4: Cartesian Therapeutics Director Michael Singer Reports Share Transactions

Director Michael Singer of Cartesian Therapeutics reported the acquisition and disposal of common stock, including shares held directly, indirectly through trusts, and as custodian for children.

Summary

• Michael Singer, a director at Cartesian Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The transactions occurred on November 19, 2024, and included the disposal of 28,821 shares of common stock at $0.
• Following these transactions, Mr. Singer directly owns 90,933 shares.
• He also has indirect ownership of 383,796 shares through a trust for his spouse and children, 56,719 shares through a trust where he is a beneficiary and trustee, 7,127 shares through a trust where he is a beneficiary, 14,788 shares held by his spouse, and 96,219 shares each held as custodian for two children.
• The filing also notes that the shares held in trust are for the benefit of his spouse and children, with his spouse acting as trustee for some of the trusts.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It is a neutral disclosure of transactions.

Industry Context

This filing is a routine disclosure of insider transactions, which is a common practice for publicly traded companies. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, as mandated by the Securities and Exchange Commission (SEC).
• The reporting of transactions by directors and officers is a common requirement to ensure transparency and prevent insider trading.
• Similar filings are made by directors and officers of companies like Amgen, Gilead Sciences, and Regeneron, which are also in the biotechnology sector.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the trading activities of a company director.
• It does not indicate any immediate impact on other stakeholders.

Key Dates

Keywords

Form 4, Beneficial Ownership, Cartesian Therapeutics, Michael Singer, Share Transactions, Director, Common Stock, Trust, Custodian